2Marcus R, Imrie K, Belch A. Treatment strategies in follicular lymphomas: current status and future perspectives [J]. J Clin Oncol, 2005, 23:6394-6399.
3Hayes DF. Follow-up of pat!ents with early breast cancer [J]. N Engl J Med, 2007, 356:2505-2513.
4Moore A. Breast cancer therapy-looking back to future [J]. N Engl J Med, 2007, 357:547-549.
5Hayat M J, Howlader N, Reichman ME, et al. Overall survival of patients with advanced eoloreetal cancer correlates with availability of fluorouracil, Mnoteean, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line[J]. J Clin Oneol, 2005, 23:9441-9442.
6Waechter F. Significant progress in palliative treatment of non small cell lung cancer in the past decade [J]. Chest, 2005, 127:738-747.
7Yin W, Chen B, Tian F, et al. The growth of radiation ontology in China's Mainland during the last 10 years[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3):795-798.
8Levegrun S, Jackson A, Zelefsky MJ, et al. Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models [J]. Int J Radiat Oncol Biol Phys, 2000, 47(5):1245-1260.
9Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis Of 938 patients irradiated in the prostate specific antigen era[J]. Cancer, 1997, 79(7):1370-1380.
10Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized dose escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer[J]. J Clin Oncol, 2000, 18(23):3904-3911.
